Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

This corrigendum clarifies that withdrawal rates due to treatment-related side effects were misstated in a study on topical finasteride for male androgenetic alopecia; higher withdrawal rates were associated with oral finasteride, not topical.

In this study, baricitinib for severe alopecia areata showed sustained efficacy over 104 weeks, with most Week-52 responders maintaining significant hair regrowth and some mixed responders improving further with long-term treatment.

This Phase 1 study reported that topical application of BPM31543 was safe and well-tolerated in patients receiving taxane-based chemotherapy, with some experiencing less than 50% hair loss, suggesting potential efficacy in reducing chemotherapy-induced alopecia, although no maximum tolerated dose was identified.

Using mirabegron and solifenacin together is safe and more effective for treating overactive bladder than using either drug alone.

This study reported that topical BPM31543 was safe and well-tolerated for patients on taxane-based chemotherapy, with some efficacy indicated in reducing hair loss at all dosages tested.

This meta-analysis found that deuruxolitinib significantly improved hair regrowth and patient satisfaction in those with moderate to severe alopecia areata compared to placebo, though it was associated with manageable side effects such as elevated creatinine kinase levels, headaches, and acne, especially at higher doses.

This systematic review and meta-analysis reported that deuruxolitinib is effective for hair regrowth and improving patient-reported outcomes in individuals with moderate to severe alopecia areata, but observed manageable treatment-emergent adverse events such as elevated creatinine kinase levels and headaches, particularly with higher doses.

Saw palmetto helps with nighttime urination and urine flow, similar to finasteride.

This article discusses androgenetic alopecia as a potential early marker for benign prostatic hyperplasia but reports no new clinical findings.

This study concluded that bimatoprost 0.03%, applied either twice or once daily, is safe, well-tolerated, and effective in improving eyebrow fullness and darkness in individuals with eyebrow hypotrichosis.

This phase 3 trial found that over 50% of adolescents with severe alopecia areata achieved successful hair regrowth after 52 weeks on baricitinib 4-mg, with no new safety concerns reported compared to existing safety profiles.

Using 5% minoxidil foam twice daily can help regrow hair, especially in younger men aged 20-30.

This review discusses the preclinical and clinical data on teriflunomide for multiple sclerosis, highlighting its selective action on immune cells without causing clinical immune suppression, and provides no new clinical results.

This study summarizes how the IL-23/IL-17 axis contributes to inflammatory skin diseases like psoriasis and highlights that biologics targeting this pathway, including monoclonal antibodies against IL-23 and IL-17, have shown efficacy in clinical trials for these conditions.

This article describes the development milestones and recent approvals of ritlecitinib for treating severe alopecia areata, with approvals in the USA and Japan and ongoing regulatory reviews in other regions.

In this phase 2 study, baricitinib at 2 mg and 4 mg doses significantly improved hair regrowth in adults with alopecia areata and ≥50% scalp hair loss compared to placebo, without new safety concerns, although the small sample size limits the results' generalizability.

This review discusses baricitinib's applications for various inflammatory disorders and highlights its promising efficacy alongside potential adverse effects, advocating for further research before it becomes a standard treatment.

This study found that oral JAK inhibitors are effective and generally well-tolerated for treating alopecia areata, but high recurrence rates after stopping treatment suggest the need for continuous use.

This review outlines the main findings from clinical trials on teriflunomide's efficacy and safety for relapsing multiple sclerosis, noting clinical considerations and exploring its mechanisms based on various studies.

This study found that colchicine treatment significantly reduced hair fiber elongation in cultured hair follicles and altered protein expression and activity in dermal papilla cells, suggesting a role for the ubiquitin-proteasome system in its effects.

This review discusses the pharmacological profile of teriflunomide for treating relapsing multiple sclerosis, highlighting its safety and effectiveness in reducing relapses and slowing disability progression, though direct comparisons with other oral medications are lacking.

This review discusses the therapeutic properties of polydeoxyribonucleotides derived from marine organisms for wound healing and inflammation, but it reports no new clinical results.

This review summarizes clinical trials and comparative studies showing that latanoprostene bunod 0.024% is effective and safe for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension, detailing its mechanism and side effects while considering its therapeutic role.

This review highlights that clascoterone, a newly FDA-approved topical androgen antagonist, effectively reduces both non-inflammatory and inflammatory acne lesions with no systemic effects, making it a promising new option for acne treatment in both male and female patients.

This study on Alzheimer's patients found that chronic sodium selenate treatment (up to 23 months) was safe and well-tolerated, with most adverse events being mild, and suggested potential slowing of cognitive decline, though confirmation requires further controlled studies.

This source reports that tofacitinib and ruxolitinib showed potential efficacy and acceptable safety profiles in treating various autoimmune disorders, including alopecia areata and psoriasis, based on a review of clinical studies, while recommending physicians consider the individual risks and benefits.

This source reports that a network meta-analysis found oral baricitinib and ruxolitinib to be effective and safe for treating alopecia areata, significantly improving response rates over placebos and showing fewer adverse effects than steroid treatments, though precise dosing needs further study.